Share on StockTwits

KYTHERA Biopharmaceuticals (NASDAQ:KYTH) Director Nathaniel E. David sold 1,230 shares of the company’s stock in a transaction that occurred on Monday, June 2nd. The stock was sold at an average price of $32.56, for a total value of $40,048.80. Following the sale, the director now directly owns 494,655 shares in the company, valued at approximately $16,105,967. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link.

Shares of KYTHERA Biopharmaceuticals (NASDAQ:KYTH) traded down 1.57% during mid-day trading on Tuesday, hitting $32.00. The stock had a trading volume of 159,051 shares. KYTHERA Biopharmaceuticals has a one year low of $21.21 and a one year high of $56.36. The stock has a 50-day moving average of $33.69 and a 200-day moving average of $40.06. The company’s market cap is $725.0 million.

KYTHERA Biopharmaceuticals (NASDAQ:KYTH) last posted its quarterly earnings results on Thursday, May 8th. The company reported ($3.18) EPS for the quarter, missing the Thomson Reuters consensus estimate of ($0.67) by $2.51. Analysts expect that KYTHERA Biopharmaceuticals will post $-3.33 EPS for the current fiscal year.

KYTHERA Biopharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of prescription products for the aesthetic medicine market.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.